CD274 and neoplasm: Aforementioned, HR+ breast tumors harbour a lower tumor mutational burden (Thomas et al., 2018; Barroso-Sousa et al., 2020) coupled to significantly lower expression levels of MHC class I and PDL1 compared to other breast cancer subtypes (Zhang et al., 2017; Onkar et al., 2023).